Literature DB >> 8797753

What is the natural history of recurrent acute otitis media in infancy?

O P Alho1, E Läärä, H Oja.   

Abstract

BACKGROUND: Chemoprophylaxis or tympanostomy tubes are often recommended for recurrent acute otitis media because of the associated morbidity, temporary hearing loss, financial costs, and risks of middle-ear sequelae. The aim of this study was to study the natural course of recurrent acute otitis media in infancy without such prophylactic treatment.
METHODS: Two hundred twenty-two children who had recurrent acute otitis media and received no prophylaxis were monitored for subsequent acute otitis media and the development of chronic otitis media with effusion.
RESULTS: Only 4% of the 222 infants with recurrent acute otitis media developed chronic otitis media with effusion and an additional 12% continued having recurrent episodes. The most significant factor predicting an increased risk of recurrence was young age (< 16 months of age). Attending day care and having siblings had a less pronounced effect.
CONCLUSIONS: Spontaneous recovery from recurrent acute otitis media is common with increasing age. Thus, until reliable causal evidence between recurrent otitis media and developmental disability is presented, chemoprophylaxis or tympanostomy tubes seem superfluous for most infants after the age of 16 months.

Entities:  

Mesh:

Year:  1996        PMID: 8797753

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  12 in total

1.  Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years.

Authors:  R A Damoiseaux; F A van Balen; A W Hoes; T J Verheij; R A de Melker
Journal:  BMJ       Date:  2000-02-05

Review 2.  Ten-Year Study of the Stringently Defined Otitis-prone Child in Rochester, NY.

Authors:  Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2016-09       Impact factor: 2.129

3.  Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children.

Authors:  Ravinder Kaur; Janet R Casey; Michael E Pichichero
Journal:  Vaccine       Date:  2010-12-01       Impact factor: 3.641

Review 4.  Antibiotic treatment of acute otitis media in children under two years of age: evidence based?

Authors:  R A Damoiseaux; F A van Balen; A W Hoes; R A de Melker
Journal:  Br J Gen Pract       Date:  1998-12       Impact factor: 5.386

5.  Poor memory B cell generation contributes to non-protective responses to DTaP vaccine antigens in otitis-prone children.

Authors:  S Basha; M E Pichichero
Journal:  Clin Exp Immunol       Date:  2015-09-30       Impact factor: 4.330

6.  Factors associated with tympanostomy tube insertion among preschool-aged children in the United States.

Authors:  M D Kogan; M D Overpeck; H J Hoffman; M L Casselbrant
Journal:  Am J Public Health       Date:  2000-02       Impact factor: 9.308

7.  Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.

Authors:  Dabin Ren; Anthony L Almudevar; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  A longitudinal study of risk factors for otitis media in African American children.

Authors:  Susan A Zeisel; Joanne E Roberts; Margaret Burchinal; Eloise Neebe; Frederick W Henderson
Journal:  Matern Child Health J       Date:  2002-09

9.  Reducing the frequency of acute otitis media by individualized care.

Authors:  Michael E Pichichero; Janet R Casey; Anthony Almudevar
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

10.  Adenoidectomy versus chemoprophylaxis and placebo for recurrent acute otitis media in children aged under 2 years: randomised controlled trial.

Authors:  Petri Koivunen; Matti Uhari; Jukka Luotonen; Aila Kristo; Risto Raski; Tytti Pokka; Olli-Pekka Alho
Journal:  BMJ       Date:  2004-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.